Designed to prevent reherniation

Publication Synopsis

Barricaid[®] Evidence-Based Value Proposition in 5 Steps



Burns no

bridges

BARRICAID® ANNULAR CLOSURE

The Barricaid[®] Annular Closure Device is an implantable device designed to prevent reherniation following limited discectomy in patients with large annular defects, who are at the highest probability of recurrent herniation if treated with just a lumbar discectomy without annular closure.

This document was developed to provide the reader with a synopsis of relevant published clinical data as it pertains to the clinical need for annular closure treatment, the patient population and prevalence, as well as to the safety and effectiveness of the Barricaid implant.

This document is not intended to be an exhaustive listing of all relevant publications, but rather an attempt to provide the reader with a condensed yet comprehensive overview of relevant published literature.

For a complete literature ov <u>Overview</u>.

The Barricaid is indicated for reducing the incidence of reherniation and reoperation in skeletally mature patients with radiculopathy (with or without back pain) attributed to a posterior or posterolateral herniation, and confirmed by history, physical examination and imaging studies which demonstrate neural compression using MRI to treat a large anular defect (between 4-6 mm tall and between 6-10 mm wide) following a primary discectomy procedure (excision of herniated intervertebral disc) at a single level between L4 and S1.

Please refer to the package insert and other labeling for a complete list of indications, contraindications, precautions and warnings (www. barricaid.com/instructions).

Introduction

For a complete literature overview, see MLT64 Published Evidence

INDICATIONS

Clinical Need

Lumbar discectomy outcomes are great in 80% of the patients

Source: CHARS 1997-2007 Based on Kaplan Meier hazard estimates

Fig. 1 Eleven-year cumulative incidence of reoperation after decompresson surgery for herniated disc in Washington State (solid line). The figure is annotated with point estimates for reoperation rates from other studies on decompression surgery (clinical and administrative). CHARS, Comprehensive Hospital Abstract Reporting System; RCT, randomized control trial.

30% of patients have large annular defects and account for 70% of all reoperations

Spine

SPINE Volume 43, Number 5, pp E308-E315 © 2018 The Author(s). Published by Wolters Kluwer Health, Inc.

LITERATURE REVIEW

OPEN

Association of Annular Defect Width After Lumbar Discectomy With Risk of Symptom **Recurrence and Reoperation**

Systematic Review and Meta-analysis of Comparative Studies

Larry E. Miller, PhD,* Matthew J. McGirt, MD,[†] Steven R. Garfin, MD,[‡] and Christopher M. Bono, MD[§]

Study Design. Systematic review and meta-analysis of comparative studies

Objective. To characterize the association of annular defect width after lumbar discectomy with the risk of symptom recurrence and reoperation

Summary of Background Data. Large annular defect width after lumbar discectomy has been reported to increase risk of symptom recurrence. However, this association has not been evaluated in a systematic manner.

Methods. A systematic literature search of MEDLINE and EMBASE was performed to identify comparative studies of large versus small annular defects following lumbar discectomy that reported symptom recurrence or reoperation rates. Main outcomes were reported with pooled odds ratios (OR) and 95% confidence intervals (CIs). Sensitivity analyses were performed to assess the robustness of the meta-analysis findings.

Results. After screening 696 records, we included data from 7 comparative studies involving 1653 lumbar discectomy patients, of whom 499 (30%) had large annular defects and 1154 (70%) had small annular defects. Methodological quality of studies was good overall. The median follow-up period was 2.9 years. The risk

From the *Miller Scientific Consulting, Inc., Asheville, NC; [†]Department of Neurological Surgery, Carolina Neurosurgery and Spine Associates, Char-lotte, NC; [‡]Department of Orthopedic Surgery, UC San Diego Health, La Jolla, CA; and [§]Department of Orthopedic Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.

Acknowledgment date: September 14, 2017. First revision date: October 19, 2017. Acceptance date: November 3, 2017.

The manuscript submitted does not contain information about medical device(s)/drug(s

Intrinsic Therapeutics, Inc. (Woburn, MA, USA) funds were received in support of this work.

Relevant financial activities outside the submitted work: board membership, consultancy, grants, expert testimony

This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used nercially without permission from the journal

Address correspondence and reprint requests to Larry E. Miller, PhD, Miller Scientific Consulting, Inc, 1854 Hendersonville Rd, 231, Asheville, NC 28803; E-mail: larry@millerscientific.com

DOI: 10.1097/BRS.000000000002501

E308 www.spinejournal.com

of symptom recurrence (OR = 2.5, 95% CI = 1.3-4.5, P = 0.004) and reoperation (OR = 2.3, 95% CI = 1.5-3.7, P < 0.001) was higher in patients with large versus small annular defects. Publication bias was not evident. The associations between annular defect width and risk of symptom recurrence and reoperation remained statistically significant in all sensitivity analyses.

Conclusion. Annular defect width after lumbar discectomy is an under-reported modifier of patient outcome. Risk for symptom recurrence and reoperation is higher in patients with large versus small annular defects following lumbar discectomy. Key words: annulus, comparative studies, disc herniation, discectomy, fragment type, lumbar, meta-analysis, microdiscectomy, reherniation, systematic review. Level of Evidence: 2

Spine 2018;43:E308-E315

umbar discectomy is performed on nearly 500,000 patients per year in the United States.¹ While this procedure is successful in most patients, symptom recurrence related to reherniation is reported in 7% to 18% of patients.²⁻⁴ Recurrent symptomatic herniation is associated with poor clinical outcome and often requires a technically demanding reoperation.⁵ Commonly reported risk factors for recurrence include disc degeneration,⁶ age,⁷ sex,⁶ and body mass index.8 However, the influence of surgery-related factors on recurrence risk is unclear. Carragee et al⁹ identified postsurgical annular defect size as a risk factor for symptom recurrence. In this study, patients with large versus small annular defects had higher rates of symptom recurrence and reoperation. However, the association of postsurgical annular defect width with symptom recurrence risk has not been evaluated in a systematic manner. The purpose of this systematic review and meta-analysis was to characterize the association of annular defect width after lumbar discectomy with the risk of symptom recurrence and reoperation.

MATERIALS AND METHODS

Study Selection

This study was performed according to the guidelines specified in the Preferred Reporting Items for Systematic Reviews

March 2018

Study Highlight

Risk in patients with large vs. small annular defects

	Odds Ratio (OR)	95% Confidence Interval (CI)
Symptom Recurrence	2.5	1.3 - 4.5
Reoperation	2.3	1.5 - 3.7

Study Summary

- Defects that are at least as wide as than a number-1 Penfield probe (6mm) are classified as large defects.
- 7 comparative studies involving 1,653 lumbar discectomy patients showed 30% of patients having large annular defects.
- The risk of reoperation was 2.3x greater in patients with large versus small annular defects.

KEY TAKEAWAYS

- Discectomy patients with large annular defects have the highest failure rate by recurrence (27%) and reoperation (21%) – while small defects have the lowest failure rate (1.1%).⁵
- Multicenter RCT provides level 1 evidence and confirms large defects being a prognostic biomarker of risk recurrence of 25% at 2 years.⁶

Literature References

- 4. Miller et al, Association of Annular Defect Width After Lumbar Discectomy With Risk of Symptom Recurrence and Reoperation. Spine (Phila Pa 1976). 2018 Mar 1;43(5):E308-E315.
- 5. Carragee et al, Clinical Outcomes After Lumbar Discectomy for Sciatica: The Effects of Fragment Type and Anular Competence, J Bone Joint Surg Am. (2003) Jan;85-A(1):102-8.
- 6. Thome et al, Annular closure in lumbar microdiscectomy for prevention of reherniation: a randomized clinical trial., Spine J. 2018 Dec;18(12):2278-2287

p=0.004 p<0.001

P-value

Preventing Disability

Discectomy reoperations are inferior to primary with 3 times the disability

ClinicoEconomics and Outcomes Research

8 Open Azzess Full Text Article

ORIGINAL RESEARCH

Dovepress

349

Post-lumbar discectomy reoperations that are associated with poor clinical and socioeconomic outcomes can be reduced through use of a novel annular closure device: results from a 2-year randomized controlled trial

> This article was published in the following Dove Press journal ClinicoEconomics and Outcomes Research

Peter Douglas Klassen¹ Wellington K Hsu² Frederic Martens³ lason A Inzana⁴ Wimar A van den Brink⁵ Michael W Groff⁶ Claudius Thomé⁷

Department of Neurosurgery, St. Bonifatius Hospital, Lingen, Germany; ²Department of Orthopaedic Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA; ³Department of Neurosurgery, OLV Ziekenhuis, Aalst, Belgium; ⁴Telos Partners LLC, Denver, CO, USA; 5Neurochirurgisch Centrum Zwolle, Zwolle, the Netherlands; ⁶Neurosurgical Spine Service, Brigham and Women's Hospital, Boston, MA, USA; 7Department of Neurosurgery, Innsbruck Medical University, Innsbruck, Austria

Introduction: Lumbar discectomy patients with large annular defects are at a high risk for reherniation and reoperation, which could be mitigated through the use of an annular closure device (ACD). To identify the most effective treatment pathways for this high-risk population, it is critical to understand the clinical outcomes and socioeconomic costs among reoperated patients as well as the utility of ACD for minimizing reoperation risk.

Methods: This was a post hoc analysis of a prospective, multicenter, randomized controlled trial (RCT) designed to investigate the safety and efficacy of an ACD. All 550 patients (both ACD treated and control) from the RCT with follow-up data through 2 years were included in this analysis (69 reoperated and 481 non-reoperated). Reoperations were defined as any revision surgery of the index level, regardless of indication. Equivalent U.S. Medicare expenditures for reoperations were estimated through cost multipliers derived from the commercially available PearlDiver database

Results: A significantly greater number of control patients (45/278; 16%) compared to ACD patients (24/272; 9%) underwent a revision surgery at the index level within 2 years of followup (p=0.01). At 2 years of follow-up, the reoperated patients had significantly worse Oswestry Disability Index scores and visual analog scale for leg and back pain scores compared to their non-reoperated counterparts (p<0.0001). The total estimated direct medical costs for reoperation were US \$952,348 (\$13,802 per reoperated patient), with control patients accounting for the majority of this cost burden (\$565,188; 59%).

Conclusion: Post-discectomy reoperation is associated with significantly increased patient morbidity, missed work, and direct treatment costs in a population at high risk for reherniation. Annular closure helped minimize this clinical and socioeconomic burden by reducing the incidence of reoperation by nearly 50% (16% control vs 9% ACD).

Keywords: lumbar discectomy, annular closure device, patient-reported outcomes, direct costs, reherniation, reoperation

Introduction

Correspondence: Jason Inzana Telos Partners LLC, 4484 Hamilton Ct. Boulder, Denver, CO 80305, USA Tel +1 720 256 7036 Email jinzana@telospartnersllc.com

Dovepress 🖬 У in 🕨

Lumbar discectomy is a highly effective procedure to address back and leg pain associated with intervertebral disc herniation and is one of the most common spinal procedures globally. In the USA alone, the procedure is performed on nearly 500,000 patients per year.1 Retrospective studies have reported lumbar discectomy

ClinicoEconomics and Outcomes Research 2018:10 349-357 © 1018 Russen et al. This work is published and licensed by Dowe Medical Press Limited. The full terms of this license are available at https://www.dowepres.new/terms. pp and incorporate the (reastine Karobineton – Nos Connervial Jupporent, v120) License (https://onsisteconnens.cog/license/b-wol/30/) by accessing the work yes hereby accept the forms. Non-connectional uses of the work as persisted without any persisted work on persisted without any other persistion for connectial use of this work as persisted without a generative without any further persistion for the Dowe Medical Press Limited, persided the work is perpendy attributed. For persisten for connectial use of this work, please see paragraphs 42 and 5 of ear Terms (http://www.dowepres.com/terms.php).

- These results are devastating from a patient and societal perspective.

KEY TAKEAWAYS

- Current level 1 evidence demonstrates that, in appropriately selected patient populations, implantation of a bone-anchored annular closure device (ACD) reduces the risk of symptom recurrence and revision surgery compared to discectomy alone (ISASS Guideline).⁸
- Reoperations have greater disability and higher use of opioids.^{3,9}
- Revision patients at higher risk of reherniation and subsequent reoperation.⁹ •

Literature References

- 7. Klassen et al, Post-lumbar discectomy reoperations that are associated with poor clinical and socioeconomic outcomes can be reduced through use of a novel annular closure device:. Clinicoecon Outcomes Res. 2018; 10: 349–357.
- 8. Lorio et al, ISASS Spine Surgery Policy 2019 Surgeocal Treatment of Lumbar Disc Hernaition with Radiculopathy, Intl J Spine Surgery Vol 14, No 1, 2020 pp 1-17
- 9. Ahn et al, Primary versus revision single-level minimally invasive lumbar discectomy, Spine (2015); 40:E1025-E1030

Annular Closure Treatment

Barricaid cuts reherniation & reoperation rates by 50-60% in patients with large defects

Burns No Bridges

Barricaid does not compromise or complicate revision options

DRIGINAL ARTICLE Study Highlight 100 ACD Control Reoperation After Primary Lumbar Discectomy with or without Implantation of a 80 Bone-Anchored Annular Closure Device: Surgical Strategies and Clinical Outcomes Peter D. Klassen¹, Geoffrey Lesage², Larry E. Miller³, Robert Hes⁴, Jasper F.C. Wolfs⁵, Sandro Eustacchio⁶, 60 Peter Vajkoczy INTRODUCTION OBJECTIVE: To determine whether presence of a boneanchored annular closure device (ACD) impacts reoperaumbar discectomy provides relief from sciatica in most tion strategies and subsequent outcomes. patients1,2 and is one of the most commonly performed Leg Pain spine surgeries.³ However, approximately 10% of surgical METHODS: Patients with large annular defects after Patient- reported outcomes after fusion patients require a repeat operation within 4 years mainly single-level limited lumbar discectomy were randomly because of inadequate symptom relief or symptom recurrence.445 allocated to receive an ACD or discectomy alone (controls) One of the strongest risk factors for symptom recurrence after and were followed for at least 3 years. lumbar discectomy is a postoperative defect of at least 6 mm width Study Summary in the annulus fibrosus.6,7 A large annular defect may allow RESULTS: Among 550 patients, reoperation risk was pressurized nuclear material to enter the extradiscal space and lower with ACD (11.0% vs. 19.3%). The types of reopreproduce radicular symptoms caused by local inflammatory reerations and operative time were similar in each group, actions and/or mechanical nerve root compression. In a alone and the ACD did not interfere with surgical planning or meta-analysis comparing patients with large (≥6 mm width) operative technique. Fusion success was 87% with ACD versus small (<6 mm width) annular defects, large defects were versus 85% for controls. Perioperative complications associated with more than a 2-fold increase in symptom recuroccurred in 22% and 19% of reoperations, respectively. rence and reoperation risk over approximately 3 years follow-up.6 interfere with surgical planning or operative technique Leg pain and back function were improved with ACD Reoperations for lumbar herniation are more costly⁸ and less effective499 than primary procedures. This has prompted develversus controls after fusion procedures, and no opment of technologies intended to repair large postoperative Perioperative complications equivalent in both groups (22% vs 19%) group differences were observed after non-fusion defects to lower recurrence rates in this high-risk patient popureoperations. lation.10 In a randomized trial of 554 patients with large Fusion success equivalent in both groups (87% vs 85%) CONCLUSIONS: In patients undergoing postpostoperative annular defects, a bone-anchored annular closure device (ACD) implanted at discectomy completion significantly discectomy reoperation, patients with an ACD were lowered the risk of recurrence and reoperation over 2 years of treated with similar operative techniques, were not follow-up11 and was shown to be highly cost-effective12 versus exposed to additional surgical risks, and reported discectomy alone. Among patients treated with an ACD who comparable clinical outcomes versus those without an require a reoperation, the impact of an ACD on procedural **KEY TAKEAWAYS** ACD. complexity and subsequent clinical outcomes is unclear. In this post hoc analysis from a randomized trial, our objective was to

Key words

- Annulus fibrosus Discectomy
- Fusion
- Revision
- Sciatica

Abbreviations and Acronyms

ACD: Annular closure device **ODI:** Oswestry Disability Index

From the ¹Department of Neurosurgery, Bonifatius Hospital, Lingen, Germany, ²Department of Neurosurgery, OLV Ziekenhuis, Aalst, Belgium; ³Miller Scientific Consulting, Inc.

Asheville, North Carolina, USA; ⁴Department of Neurosurgery, AZ Klina, Brasschaat, Belgium; ^{\$}Department of Neurosurgery, Haaglanden Medical Center Westeinde Antoniushove, Leidschendam, The Netherlands; ⁶Department of Neurosurgery, Medical University Graz, Graz, Austria; and ⁷Department of Neurosurgery, Charité Universitätsmedizin, Berlin, Germany

To whom correspondence should be addressed: Peter D. Klassen, M.D. [E-mail: PeterDouglas.Klassen@hospital-lingen.de]

Citation: World Neurosurg. (2019). https://doi.org/10.1016/j.wneu.2019.07.038

Journal homepage: www.journals.elsevier.com/world-neurosurgery

Available online: www.sciencedirect.com 1878-8750/\$ - see front matter © 2019 Published by Elsevier Inc

- outcomes versus those without.14
- Vertebral endplate changes did not present an additional risk factor for patients implanted with Barricaid.15
- Reoperated Barricaid patients fare no worse than reoperated discectomy patients.

Literature References

- 14. Klassen et al, Reoperation After Primary Lumbar Discectomy with or without Implantation of a Bone-Anchored Annular Closure Device: Surgical Strategies and Clinical Outcomes. World Neurosurgery Volume 130, October 2019, Pages e926-e932
- 15. Kursumovic et al, Clinical implications of vertebral endplate disruptions after lumbar discectomy: 3-year results from a randomized trial of a bone-anchored annular closure device, Journal of Pain Research 2020:13 1-7

In patients undergoing post-discectomy reoperation, patients with a Barricaid reported comparable clinical

Notes	

The Evidence-Based Annular Closure Treatment

Lumbar discectomy outcomes are great in 80% of the patients

30% of patients have large annular defects and account for 70% of all reoperations

Discectomy reoperations are inferior to primary with 3 times the disability

Barricaid cuts reherniation & reoperation rates by 50-60% in patients with large defects

Barricaid does not compromise or complicate revision options

Intrinsic Therapeutics, Inc. 30 Commerce Way Woburn, MA 01801 USA +1 781 932 0222 info@barricaid.com www.barricaid.com

Barricaid has been used to improve outcomes in 7500+ patients over more than 10 years. WARNING: This product has labeling limitations. See package insert for additional warnings, precautions and possible adverse effects. CAUTION: USA law restricts this device to sale by or on the order of physician. All medical devices have associated risks. Please refer to the package insert and other labeling for a complete list of indications, contraindications, precautions and warnings (www.barricaid.com/us-en/instructions). For further information on Barricaid, contact your Intrinsic representative.

ALT63-A-EN Rev. C

Registered trademarks of Intrinsic Therapeutics, Inc. ©2020 Intrinsic Therapeutics, Inc. All Rights Reserved.